We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Patterson Companies Inc. (PDCO - Free Report) reported fourth-quarter fiscal 2016 adjusted earnings of 77 cents per share from continuing operations that beat the Zacks Consensus Estimate by a penny and improved 35.1% year over year on higher sales.
Net sales from continuing operations increased 40.5% (41.6% on a constant currency basis) year over year to $1.45 billion, which narrowly missed the Zacks Consensus Estimate of $1.47 billion. However, the year-over-year improvement reflected robust performance by the Animal Health division.
Patterson Animal Health (54% of total sales) sales surged almost 119.3% on a year-over-year basis to $780.8 million (121.6% on a constant currency basis) on the back of a 127.7% increase in consumable and printed products sales. Sales of other services and products improved almost 40%. Animal Health International contributed $403.6 million to net sales.
The strong year-over-year upside was driven by solid results in the U.S. companion animal business, as well as a strong contribution from the U.K. operations. These fully offset sluggish livestock end-market conditions in the quarter.
Patterson Dental (46% of total sales) sales decreased 1% to $662.1 million. Consumable sales increased 3.3% at constant currency to $354.6 million. Meanwhile, sales from dental equipment and software decreased 6.9%. Sales from other services and products climbed 3.6% on a year-over-year basis.
Gross margin contracted 280 basis points (bps) to 25% in the reported quarter.
Adjusted operating expenses, as a percentage of revenues, decreased 200 bps to 16.8%. However, adjusted operating margin contracted 80 bps to 8.2%.
Fiscal 2016 Highlights
Adjusted earnings surged 30.7% to $2.47 in fiscal 2016, driven by 37.7% increase in sales, which totaled $5.39 billion.
Patterson Companies bought back approximately 4.4 million shares worth $200 million, leaving approximately 16 million shares for repurchase under the current authorization. The company also paid dividends worth $90.6 million.
Outlook
Patterson Companies forecasts adjusted earnings in the range of $2.60--$2.70 per share, including $25 million incremental operating expenses related to the ERP implementation for fiscal 2017. The company expects North American and international markets to remain stable through fiscal 2017.
Zacks Rank & Key Picks
Patterson Companies currently has a Zacks Rank #3 (Hold).
Better-ranked stocks in the medical sector are Halyard Health , C.R. Bard and CONMED (CNMD - Free Report) . While Halyard sports a Zacks Rank #1 (Strong Buy), C.R. Bard and CONMED carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Patterson Companies (PDCO) Q4 Earnings Top, Sales Strong
Patterson Companies Inc. (PDCO - Free Report) reported fourth-quarter fiscal 2016 adjusted earnings of 77 cents per share from continuing operations that beat the Zacks Consensus Estimate by a penny and improved 35.1% year over year on higher sales.
Quarter Details
Net sales from continuing operations increased 40.5% (41.6% on a constant currency basis) year over year to $1.45 billion, which narrowly missed the Zacks Consensus Estimate of $1.47 billion. However, the year-over-year improvement reflected robust performance by the Animal Health division.
Patterson Animal Health (54% of total sales) sales surged almost 119.3% on a year-over-year basis to $780.8 million (121.6% on a constant currency basis) on the back of a 127.7% increase in consumable and printed products sales. Sales of other services and products improved almost 40%. Animal Health International contributed $403.6 million to net sales.
The strong year-over-year upside was driven by solid results in the U.S. companion animal business, as well as a strong contribution from the U.K. operations. These fully offset sluggish livestock end-market conditions in the quarter.
Patterson Dental (46% of total sales) sales decreased 1% to $662.1 million. Consumable sales increased 3.3% at constant currency to $354.6 million. Meanwhile, sales from dental equipment and software decreased 6.9%. Sales from other services and products climbed 3.6% on a year-over-year basis.
Gross margin contracted 280 basis points (bps) to 25% in the reported quarter.
Adjusted operating expenses, as a percentage of revenues, decreased 200 bps to 16.8%. However, adjusted operating margin contracted 80 bps to 8.2%.
Fiscal 2016 Highlights
Adjusted earnings surged 30.7% to $2.47 in fiscal 2016, driven by 37.7% increase in sales, which totaled $5.39 billion.
Patterson Companies bought back approximately 4.4 million shares worth $200 million, leaving approximately 16 million shares for repurchase under the current authorization. The company also paid dividends worth $90.6 million.
Outlook
Patterson Companies forecasts adjusted earnings in the range of $2.60--$2.70 per share, including $25 million incremental operating expenses related to the ERP implementation for fiscal 2017. The company expects North American and international markets to remain stable through fiscal 2017.
Zacks Rank & Key Picks
Patterson Companies currently has a Zacks Rank #3 (Hold).
Better-ranked stocks in the medical sector are Halyard Health , C.R. Bard and CONMED (CNMD - Free Report) . While Halyard sports a Zacks Rank #1 (Strong Buy), C.R. Bard and CONMED carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>